Oro-myofunctional Characteristics and Obstructive Sleep Apnea in Infants With Down Syndrome

Recruiting Observational Study
Obstructive Sleep Apnea Down Syndrome (Trisomy 21)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
5 Months – 6 Months
Sex
Any
Study type
Observational
Participants needed
30 (estimated)
Sponsor
Hospices Civils de Lyon · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Obstructive Sleep Apnea (OSA) is characterised by repetitive collapse of the upper airway during sleep, inducing breathing disturbances that can result in oxygen desaturation and frequent arousals. In children, OSA can have long-term consequences on the development and on the cardiovascular system. Down Syndrome (DS) is a genetic disorder associated with intellectual disability and many comorbidi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: (infants with Down Syndrome) * Aged 6 months (±3 weeks) * Diagnosed with Trisomy 21 * Affiliated to a social security scheme * With informed consent of the 2 legal representatives Exclusion Criteria: * Diagnosed with mosaic Down syndrome * Born preterm (gestation age at birth…
Contacts

Patricia PF FRACO, MD, PhD

+33 4 27 85 60 52

patricia.franco@chu-lyon.fr

CONTACT

Aurore GUYON, PHD

+33 4 27 85 52 47

aurore.guyon@chu-lyon.fr

CONTACT